A novel mutation in MECOM affects MPL regulation in vitro and results in thrombocytopenia and bone marrow failure
British Journal of Haematology · 2023
DOI: 10.1111/bjh.19023 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Daniele Ammeti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy. Hauptthemen laut MEDLINE: Thrombocytopenia, Pancytopenia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Italian Ministry of Health, Associazione di Promozione Sociale "Genitori in fuga", Ministero della Salute.
Abstract (Originalsprache)
MECOM‐associated syndrome (MECOM‐AS) is a rare disease characterized by amegakaryocytic thrombocytopenia, progressive bone marrow failure, pancytopenia and radioulnar synostosis with high penetrance. The clinical phenotype may also include finger malformations, cardiac and renal alterations, hearing loss, B‐cell deficiency and predisposition to infections. The syndrome, usually diagnosed in the neonatal period because of severe thrombocytopenia, is caused by mutations in the MECOM gene, encoding for the transcription factor EVI1. The mechanism linking the alteration of EVI1 function and thrombocytopenia is poorly understood. In a paediatric patient affected by severe thrombocytopenia, we identified a novel variant of the MECOM gene (p.P634L), whose effect was tested on pAP‐1 enhancer element and promoters of targeted genes showing that the mutation impairs the repressive activity of the transcription factor. Moreover, we demonstrated that EVI1 controls the transcriptional regulation of MPL , a gene whose mutations are responsible for congenital amegakaryocytic thrombocytopenia (CAMT), potentially explaining the partial overlap between MECOM‐AS and CAMT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy.
- Pediatric Hematology, Oncology and Stem Cell Transplant Division, Padua University Hospital, Padua, Italy.
- Maternal and Child Health Department, Padua University, Padua, Italy.
- Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy.
ORCID-Profile: Daniele Ammeti, Maria Gabelli, Anna Savoia, Silvia Bresolin, Michela Faleschini
Förderung
- Italian Ministry of Health
- Associazione di Promozione Sociale "Genitori in fuga"
- Ministero della Salute
Zitieren
APA
Ammeti, D., Marzollo, A., Gabelli, M., Zanchetta, M. E., Tretti-Parenzan, C., Bottega, R., Capaci, V., Biffi, A., Savoia, A., Bresolin, S., & Faleschini, M. (2023). A novel mutation in MECOM affects MPL regulation in vitro and results in thrombocytopenia and bone marrow failure. British Journal of Haematology. https://doi.org/10.1111/bjh.19023
Vancouver
Ammeti D, Marzollo A, Gabelli M, Zanchetta ME, Tretti-Parenzan C, Bottega R, et al. A novel mutation in MECOM affects MPL regulation in vitro and results in thrombocytopenia and bone marrow failure. British Journal of Haematology. 2023. doi:10.1111/bjh.19023
BibTeX
@article{Ammeti2023,
author = {Ammeti, Daniele and Marzollo, Antonio and Gabelli, Maria and Zanchetta, Melania Eva and Tretti-Parenzan, Caterina and Bottega, Roberta and Capaci, Valeria and Biffi, Alessandra and Savoia, Anna and Bresolin, Silvia and Faleschini, Michela},
title = {A novel mutation in MECOM affects MPL regulation in vitro and results in thrombocytopenia and bone marrow failure},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.19023}
}
EUVIMED